Ferrer-Mallol Elisa, Matthews Clare, Stoodley Madeline, Gaeta Alessandra, George Elinor, Reuben Emily, Johnson Alex, Davies Elin Haf
Aparito Ltd, Wrexham, United Kingdom.
Duchenne UK, London, United Kingdom.
Front Pharmacol. 2022 Sep 12;13:916714. doi: 10.3389/fphar.2022.916714. eCollection 2022.
Digital health technologies are transforming the way health outcomes are captured and measured. Digital biomarkers may provide more objective measurements than traditional approaches as they encompass continuous and longitudinal data collection and use of automated analysis for data interpretation. In addition, the use of digital health technology allows for home-based disease assessments, which in addition to reducing patient burden from on-site hospital visits, provides a more holistic picture of how the patient feels and functions in the real world. Tools that can robustly capture drug efficacy based on disease-specific outcomes that are meaningful to patients, are going to be key to the successful development of new treatments. This is particularly important for people living with rare and chronic complex conditions, where therapeutic options are limited and need to be developed using a patient-focused approach to achieve the biggest impact. Working in partnership with patient Organisation Duchenne UK, we co-developed a video-based approach, delivered through a new mobile health platform (DMD Home), to assess motor function in patients with Duchenne muscular dystrophy (DMD), a genetic, rare, muscular disease characterized by the progressive loss of muscle function and strength. Motor function tasks were selected to reflect the "transfer stage" of the disease, when patients are no longer able to walk independently but can stand and weight-bear to transfer. This stage is important for patients and families as it represents a significant milestone in the progression of DMD but it is not routinely captured and/or scored by standard DMD clinical and physiotherapy assessments. A total of 62 videos were submitted by eight out of eleven participants who onboarded the app and were analysed with pose estimation software (OpenPose) that led to the extraction of objective, quantitative measures, including time, pattern of movement trajectory, and smoothness and symmetry of movement. Computer vision analysis of video tasks to identify voluntary or compensatory movements within the transfer stage merits further investigation. Longitudinal studies to validate DMD home as a new methodology to predict progression to the non-ambulant stage will be pursued.
数字健康技术正在改变健康结果的获取和衡量方式。数字生物标志物可能比传统方法提供更客观的测量,因为它们涵盖连续和纵向的数据收集,并使用自动分析来解释数据。此外,数字健康技术的使用允许进行居家疾病评估,这除了减轻患者因现场医院就诊带来的负担外,还能更全面地了解患者在现实世界中的感受和功能。能够基于对患者有意义的疾病特定结果有力地捕捉药物疗效的工具,将是新疗法成功开发的关键。这对于患有罕见和慢性复杂疾病的人尤为重要,在这些疾病中,治疗选择有限,需要采用以患者为中心的方法来开发,以实现最大影响。我们与患者组织英国杜氏肌营养不良症协会合作,共同开发了一种基于视频的方法,通过一个新的移动健康平台(DMD Home)来评估杜氏肌营养不良症(DMD)患者的运动功能。DMD是一种遗传性、罕见的肌肉疾病,其特征是肌肉功能和力量逐渐丧失。选择运动功能任务来反映疾病的“转移阶段”,即患者不再能够独立行走,但能够站立并负重转移。这个阶段对患者和家庭很重要,因为它代表了DMD进展中的一个重要里程碑,但标准的DMD临床和物理治疗评估通常不会对其进行捕捉和/或评分。在使用该应用程序的11名参与者中,有8人提交了总共62个视频,并使用姿态估计软件(OpenPose)进行分析,从而提取了客观、定量的测量数据,包括时间、运动轨迹模式以及运动的平滑度和对称性。对视频任务进行计算机视觉分析,以识别转移阶段内的自主或代偿性运动,这值得进一步研究。将开展纵向研究,以验证DMD Home作为预测进入非行走阶段进展的新方法。